[1]
|
Molitch, M.E. (2017) Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA, 317, 516-524.
https://doi.org/10.1001/jama.2016.19699
|
[2]
|
Hansen, T.M., Batra, S., Lim, M., Gallia, G.L., Burger, P.C., Salvatori, R., et al. (2014) Invasive Adenoma and Pituitary Carcinoma: A SEER Database Analysis. Neurosurgical Review, 37, 279-285; Discussion 285-286.
https://doi.org/10.1007/s10143-014-0525-y
|
[3]
|
Yavropoulou, M.P., Tsoli, M., Barkas, K., Kaltsas, G. and Grossman, A. (2020) The Natural History and Treatment of Non-Functioning Pituitary Adenomas (Non-Functioning PitNETs). Endocrine-Related Cancer, 27, R375-R390.
https://doi.org/10.1530/ERC-20-0136
|
[4]
|
Kasuki, L. and Raverot, G. (2020) Definition and Diagnosis of Aggressive Pituitary Tumors. Reviews in Endocrine & Metabolic Disorders, 21, 203-208. https://doi.org/10.1007/s11154-019-09531-x
|
[5]
|
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., et al. (2018) European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas. European Journal of Endocrinology, 178, G1-G24. https://doi.org/10.1530/EJE-17-0796
|
[6]
|
Lopes, M.B.S. (2017) The 2017 World Health Organization Classification of Tumors of the Pituitary Gland: A Summary. Acta Neuropathologica, 134, 521-535. https://doi.org/10.1007/s00401-017-1769-8
|
[7]
|
O’Donnell, J.S., Teng, M.W.L. and Smyth, M.J. (2019) Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy. Nature Reviews Clinical Oncology, 16, 151-167. https://doi.org/10.1038/s41571-018-0142-8
|
[8]
|
Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science, 359, 1350-1355.
https://doi.org/10.1126/science.aar4060
|
[9]
|
Giraldo, N.A., Sanchez-Salas, R., David Peske, J., Vano, Y., Becht, E., Petitprez, F., et al. (2019) The Clinical Role of the TME in Solid Cancer. British Journal of Cancer, 120, 45-53. https://doi.org/10.1038/s41416-018-0327-z
|
[10]
|
Wang, P.-F., Wang, T.-J., Yang, Y.-K., Yao, K., Li, Z., Li, Y.M., et al. (2018) The Expression Profile of PD-L1 and CD8+ Lymphocyte in Pituitary Adenomas Indicating for Immunotherapy. Journal of Neuro-Oncology, 139, 89-95.
https://doi.org/10.1007/s11060-018-2844-2
|
[11]
|
Heshmati, H.M., Kujas, M., Casanova, S., Wollan, P.C., Racadot, J., Van Effenterre, R., et al. (1998) Prevalence of Lymphocytic Infiltrate in 1400 Pituitary Adenomas. Endocrine Journal, 45, 357-361.
https://doi.org/10.1507/endocrj.45.357
|
[12]
|
Lupi, I., Manetti, L., Caturegli, P., Menicagli, M., Cosottini, M., Iannelli, A., et al. (2010) Tumor Infiltrating Lymphocytes but Not Serum Pituitary Antibodies Are Associated with poor Clinical Outcome after Surgery in Patients with Pituitary Adenoma. The Journal of Clinical Endocrinology and Metabolism, 95, 289-296.
https://doi.org/10.1210/jc.2009-1583
|
[13]
|
Lu, J.-Q., Adam, B., Jack, A.S., Lam, A., Broad, R.W. and Chik, C.L. (2015) Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas. Endocrine Pathology, 26, 263-272. https://doi.org/10.1007/s12022-015-9383-6
|
[14]
|
Sato, M., Tamura, R., Tamura, H., Mase, T., Kosugi, K., Morimoto, Y., et al. (2019) Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors. Journal of Clinical Medicine, 8, Article No. 695. https://doi.org/10.3390/jcm8050695
|
[15]
|
Barry, S., Carlsen, E., Marques, P., Stiles, C.E., Gadaleta, E., Berney, D.M., et al. (2019) Tumor Microenvironment Defines the Invasive Phenotype of AIP-Mutation-Positive Pituitary Tumors. Oncogene, 38, 5381-5395.
https://doi.org/10.1038/s41388-019-0779-5
|
[16]
|
DeNardo, D.G. and Ruffell, B. (2019) Macrophages as Regulators of Tumour Immunity and Immunotherapy. Nature Reviews. Immunology, 19, 369-382. https://doi.org/10.1038/s41577-019-0127-6
|
[17]
|
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z. and Motallebnezhad, M. (2021) Immune Checkpoints and Cancer Development: Therapeutic Implications and Future Directions. Pathology—Research and Practice, 223, Article ID: 153485. https://doi.org/10.1016/j.prp.2021.153485
|
[18]
|
Topalian, S.L., Taube, J.M., Anders, R.A. and Pardoll, D.M. (2016) Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy. Nature Reviews Cancer, 16, 275-287. https://doi.org/10.1038/nrc.2016.36
|
[19]
|
Vathiotis, I.A., Gomatou, G., Stravopodis, D.J. and Syrigos, N. (2021) Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. International Journal of Molecular Sciences, 22, Article No. 5383.
https://doi.org/10.3390/ijms22105383
|
[20]
|
Marchetti, A., Di Lorito, A. and Buttitta, F. (2017) Why Anti-PD1/PDL1 Therapy Is So Effective? Another Piece in the Puzzle. Journal of Thoracic Disease, 9, 4863-4866. https://doi.org/10.21037/jtd.2017.11.105
|
[21]
|
Mei, Y., Bi, W., Greenwald, N.F., Du, Z., Agar, N.Y.R., Kaiser, U.B., et al. (2016) Increased Expression of Programmed Death Ligand 1 (PD-L1) in Human Pituitary Tumors. Oncotarget, 7, 76565-76576.
https://doi.org/10.18632/oncotarget.12088
|
[22]
|
Pollack, R., Kagan, M., Dresner-Pollak, R. and Neuman, T. (2021) PD-L1 Expression in Normal Endocrine Tissues Is Not Increased Despite High Incidence of Pd-1 Inhibitor-Associated Endocrinopathies. Endocrine Practice, 27, 34-37.
https://doi.org/10.1016/j.eprac.2020.11.004
|
[23]
|
Kemeny, H.R., Elsamadicy, A.A., Harrison Farber, S., Champion, C.D., Lorrey, S.J., Chongsathidkiet, P., et al. (2020) Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical Cancer Research, 26, 1141-1151. https://doi.org/10.1158/1078-0432.CCR-18-3486
|
[24]
|
Sol, B., de Filette, J.M.K., Awada, G., Raeymaeckers, S., Aspeslagh, S., Andreescu, C.E., et al. (2021) Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma: A New Emerging Treatment? European Journal of Endocrinology, 184, K1-K5. https://doi.org/10.1530/EJE-20-0151
|